Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.

摘要: Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody approved by the US Food and Drug Administration for treatment of colorectal (CRC) head neck (HN 21 HN 6 grade II, Ill, 2 IV). There was no V HIR. All HIRs occurred during first infusion. were differences between age, race, diagnosis, stage, concurrent chemotherapy, or radiotherapy with cetuximab, allergy history, military service era patients developing versus those who did not.There identifiable risk factors that predicted severity Neither premedication modifications (P = 0.34) nor bronchodilator use (P= 0.12) impacted incidence A cetuximab test dose successfully elicited HIR resulted in 87% cost savings. None five receiving subsequent retreatment anti-EGFR MoAb had recurrence An infusion can be a serious underestimated toxicity. The relatively high reported here consistent previously identified Southeastern United States. No clinical, demographic, historic variables reliably our population. Use to elicit appears feasible cost-effective. panitumumab after select CRC safe.